CA 125 regression after two cycles of neoadjuvant chemiotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction;Regresja markera CA 125 po dwóch kursach neoadjuwantowej chemioterapii jako czynnik prognostyczny chorych na raka jajnika i pierwotnego surowiczego raka otrzewnej poddawanych interwałowej operacji cytoredukcyjnej

Ginekologia Polska

Volumn 79, Issue 2, 2008, Pages 108-114

  Gasowska Bodnar, Agnieszka ^a   Bodnar, Lubomir ^b   Benedykt, Weisło Gabriel ^b   Jerzak, Małgorzata Maria ^a   Szezylik, Cezary ^b   Baranowski, Włodzimierz ^a  

^a Klinika Ginekologii i Ginekologii Onkologicznej   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Chemotherapy neodjuvant therapy; Gynecological surgical procedures interval surgical cytoreduction; Ovarian cancer CA 125; Ovarian cancer chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CYSTADENOCARCINOMA; FEMALE; HOSPITALIZATION; HUMAN; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PERITONEUM TUMOR; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 45549085425     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Krajowy Rejestr Nowotworów. Warszawa: Instytut Centrum Onkologii. 2005.
2. Winter W, Maxwell G, Tian C, [et al.]. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25, 3621-3627.
3. Hensley M, Castiel M, Robson M. Screening for Ovarian cancer: what we know, what we need to know. Oncology. 2000, 14, 1601-1607.
4. Frei E. Clinical cancer research: an embattled species. Cancer. 1982, 50, 1979-1992.
5. Ansquer Y, Leblanc E, Clough K, [et al.]. Neoadjuvant chemotheraphy for unresectable ovarian carcinoma: a French multicenter study. Cancer. 2001, 91, 2329-2334.
6. Bristow R, Tomacruz R, Armstrong D, [et al.]. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002, 20, 1248-1259.
7. Bristow R, Chi D. Platinum-based neoadjuvant chemotheraphy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006, 103, 1070-1076.
8. Eagle K, Ledermann J. Tumor markers in ovarian malignancies. Oncologist. 1997, 2, 324-329.
9. Rustin G, Marples M, Nelstrop A, [et al.]. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001, 19, 4054-4057.
10. Bridgewater J, Nelstrop A, Rustin G, [et. al.]. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999, 17, 501-508.
11. Kornafel J. Zalecenia postepowania diagnostyczno- terapeutycznego w nowotworach złośliwych u dorosłych. W: Ginekologia Onkologiczna. Pod red. Krzakowski M. Polska Unia Onkologii. 2003, 298-304.
12. Kuhn W, Rutke S, Späthe K, [et al.]. Neoadjuvant chemotheraphy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynaecology and Obstetrics Stage III C ovarian carcinoma. Cancer. 2001, 92, 2585-2591.
13. Chan, Y, Ng T, Ngan H, [et al.]. Quality of life in women treated with neoadjuvant chemotheraphy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol. 2003, 88, 9-16.
14. Levine D, Bonome T, Olshen A, [et al.]. Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction. In: 40th Annual Meeting Proceedings of the American Society of Clinical Oncology. Ed. Grunberg S. New Orleans (USA). June 5-8, 2004. 2004; 448.
15. Le T, Hopkins L, Faught W, [et al.]. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotheraphy and delayed primary surgical debulking. Gynecol Oncol. 2007, 105, 712-715.
16. Tate S, Hirai Y, Takeshima N, [et al.]. CA125 regression during neoadjuvant chemotheraphy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol. 2005, 96, 143-149.